Sunday, May 22, 2016 11:12:49 PM
People should always make up their own minds,.... that's what make the markets go around you know,...
The only pieces of the projections that are important are those that are long-term. And those projections are tied to milestones being made rather than a specific, calendar-driven timeline.
Those projections are still playing out,.... too early to call them failures as milestones that have not yet been achieved, but that are being diligently worked upon, as failures.
A failure would have been to submit FluCide for TOX testing and have it show unacceptable toxicity,.... as that has not been the case,... then it is not a failure.
A failure would be to have submitted HerpeCide test compounds to the 3 University Labs and have them feed back results indicating that none of the candidates are worthy of moving forward into additional testing,... as that has not yet been the case,.... then it is not a failure.
A failure would be to determine that the company was unable to move forward into Clinical testing without having built or otherwise acquired the production facility and capacity to manufacture their candidate compounds in sufficient quality and quantity to go into clinical testing. As the company has now built, equipped, staffed and is getting that plant certified to do the work,... that is not a failure.
I could go on,.... but it would be redundant and lost on most of the target audience anyway.
Have a good night and a pleasant week,.....
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM